UCBJF Stock UPDATES Ucb S A (UCBJF) 94.7900 09/13/2014 14:38

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ucb S A (UCBJF) 94.7900 $UCBJF

Roche's (RHHBY) RoActemra Gets EU Approval for Early RA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 4:20PM CDT
Positive news flowed in at Roche (RHHBY) when its RA drug RoActemra received approval from the European Commission to treat patients suffering from early RA who have previously not been treated with methotrexate (MTX).

UCB's Epilepsy Drug Vimpat's Label Expanded in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 3:45PM CDT
UCB's (UCBJF) Vimpat has been approved in the U.S. as monotherapy for the treatment of partial-onset seizures in epilepsy patients aged 17 years and above.

UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:40PM CDT
Actavis has filed an ANDA with the FDA seeking marketing approval for its generic version of UCB's Neupro. In response, UCB filed a lawsuit against Actavis.

Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid

UCB's Brivaracetam Positive in Phase III Epilepsy Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 4:40PM CDT
UCB SA (UCBJF) announced positive top-line results from a phase III study on epilepsy candidate, brivaracetam.

UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:10PM CDT
UCB SA (UCBJF) and Dermira have entered into a licensing agreement for the development and commercialization of Cimzia in dermatology.

UCB's Vimpat Positive for Partial-Onset Seizures - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 10:50AM CDT
UCB SA (UCBJF) announced positive data from two studies on Vimpat as an early adjunctive therapy in adults suffering from partial-onset seizures.

Update on Pfizer's OTC Nexium 24HR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:30PM CDT
Pfizer announced that it has received the FDA approval for its OTC version of AstraZeneca's Nexium 24HR.

Bristol Myers Deal Overshadows Q4 loss at Five Prime - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 10:00AM CDT
Amidst the excitement about the Bristol-Myers deal, Five Prime reported its fourth quarter 2013 results.

UCB to Return Tozadenant Rights - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 4:44PM CDT
UCB announced that it will return global rights to tozadenant (SYN115) to Biotie Therapies Corp.

Sanofi, UCB Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 5:10PM CDT
Sanofi entered into an agreement with UCB for the discovery and development of therapies for immune-mediated diseases including gastroenterology and arthritis.

UCB Misses Earnings Ests, Revs In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 12:32PM CST
UCB reported 2013 earnings per share of $2.56, missed the Zacks Consensus Estimate of $2.84.

UCB : CONVENING NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
Thomson Reuters ONE - Fri Feb 21, 2:01AM CST
The shareholders are invited to attend the Extraordinary General Meeting which will be held on Monday, 24 March 2014, at 09:00 am CET at the registered office of UCB SA/NV, Allee de la Recherche 60 - 1070 Brussels, for the purpose of considering the items shown on the agenda set out below.

Worldwide Nanomedicine Market Report 2013-2019: Neurology, Cardiovascular, Anti-inflammatory, Anti-infective & Oncology Applications
M2 - Wed Feb 19, 9:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4bpxtn/nanomedicine) has announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report includes market estimations for the nanomedicine market for the forecast period 2013 - 2019. The market size is represented in terms of USD billion and the market estimates and forecasts are calculated, considering 2012 as the base year. Moreover, market trends and recent developments have been kept into account while forecasting market growth and revenue for the period 2013 - 2019. The overall nanomedicine market is segmented on the basis of application and geography and the market estimations for each of these segments, in terms of USD billion, is provided in this report. The nanomedicine market, by applications is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other markets. The nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and rest of the world. The global trends such as drivers, restraints and opportunities of the global nanomedicine market is detailed in the market overview chapter of this report., with a view on impact of these factors on market growth along the course of the forecast period. The chapter on competitive landscape consists of heat map analysis of the key players operating in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global nanomedicine market is categorized into the following segments: - Neurology - Cardiovascular - Anti-Inflammatory - Anti-Infectives - Oncology - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Nanomedicine Market Overview Chapter 4 Global Nanomedicine Market, by Applications Chapter 5 Global Nanomedicine Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Abbott Laboratories - Celgene Corporation - CombiMatrix Corporation - GE Healthcare - Johnson & Johnson - Mallinckrodt plc. - Merck & Company Inc. - Nanosphere, Inc. - Pfizer Inc. - Sigma-Tau Pharmaceuticals Inc. - Teva Pharmaceutical Industries Ltd. - UCB SA For more information visit http://www.researchandmarkets.com/research/4b...nomedicine

Loss Narrows at Immunomedics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 26, 8:54AM CDT
Immunomedics reported fourth quarter 2013 loss of 9 cents per share.

Good News for RedHill Biopharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 23, 3:10PM CDT
Good news flowed in at RedHill Biopharma when the company received a positive feedback on its RHB-104.

Another Generic Launch at Mylan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 16, 9:50AM CDT
Mylan launched its generic version of Abbott Labs' Trilipix.

New Data on UCB's Cimzia - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 14, 2:48PM CDT
UCB presented new data from the RAPID-PsA study and RAPID-axSpA study on Cimzia at the European League Against Rheumatism (EULAR) Congress.

Update on UCB Lupus Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 13, 8:40PM CDT
UCB recently presented new data on its lupus candidate, epratuzumab, from an open-label extension study of the EMBLEM phase IIb study




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 161

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 24

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Dario's WebMD Deal Opens a Vast, Unproven Channel Path

Updated Category News Views 12

One partnership can look like a gold mine from across the valley; getting the ore out is another matter entirely. DarioHealth has struck a strategic partnership with WebMD Health Services that could put its multi-condition care platform in front of an enormous commercial ecosystem: more than 3,500 employers and 65 million covered lives. That is a meaningful distribution...

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 90

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 299

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading
Color Me Mine Tests Florida's Creative Leisure Demand

Updated Category News Views 72

Pottery studios are not exactly the sort of thing that makes markets pound the table, but Florida’s latest Color Me Mine push deserves a closer look. The company signed three franchise agreements in 2026 for Panama City Beach, Doral and Boca Raton, adding planned growth to a state where it already operates 11 studios. For a private franchisor, this is not a quarterly...

Continue Reading
Arbor Realty's Loan Mess Meets a Dividend Shutdown

Updated Category News Views 58

A dividend suspension lands differently when the loan book is already coughing up smoke. Arbor Realty Trust’s latest disclosed numbers are not the sort that investors can shrug off as one ugly quarter and forget by Friday. The company reported a third-quarter 2026 GAAP net loss of $85.4 million, suspended its quarterly cash dividend effective immediately, and described...

Continue Reading
Washington-to-Asia Advisory Deal Targets Policy Risk

Updated Category News Views 109

Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 56

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 51

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategic Planning for Long-Term and Short-Term Financial Success

Updated Category Investing Views 1297

Financial success rarely happens by accident. It requires deliberate planning, disciplined execution, and ongoing adjustments to align with changing circumstances. People often focus either on their short-term needs or their long-term goals, overlooking the importance of balancing them. A strong financial strategy incorporates immediate priorities while building a secure...

Continue Reading
Anticipating Caesars Entertainment's Upcoming Earnings Report

Updated Category News Views 259

A Look Ahead at Caesars Entertainment's Earnings Report Caesars Entertainment (NASDAQ: CZR) is on the verge of revealing its quarterly earnings report, drawing the interest of investors and market analysts alike. With anticipation building, here’s what the market expects before the announcement. Projected Earnings and Market Reactions Market analysts predict that...

Continue Reading
ResVita Bio's FDA Meeting Marks Progress for Netherton Syndrome

Updated Category News Views 215

ResVita Bio Advances Clinical Plans for Netherton Syndrome ResVita Bio, a biotechnology company focused on groundbreaking treatment options for skin diseases, recently shared exciting news about a pivotal meeting with the U.S. Food and Drug Administration (FDA). This engagement was crucial as it involved RVB-003, their leading investigational therapy targeted at...

Continue Reading
Solidion Technology Innovates to Advance Lithium-Sulfur Batteries

Updated Category News Views 235

Solidion Technology Makes Significant Advances in Battery Technology Solidion Technology, Inc. (NASDAQ: STI) has made remarkable progress in the field of battery technology, particularly with its lithium-sulfur (Li-S) batteries. Recently, Solidion announced a breakthrough in achieving a cell energy density of 380 Wh/kg, with future ambitions set at reaching 450 Wh/kg....

Continue Reading
Luray Peanut Co. Spices Up Snack Market with New Launch

Updated Category News Views 76

Spice Meets Peanut In An Unexpected Fusion Alright, let's shed some light on the latest concoction shaking up the snacking aisle. Luray Peanut Company has teamed up with none other than Texas Pete® to create a spicy new twist on boiled peanuts. Trust me, this is no typical snack partnership. Instead, it's the kind of daring venture that screams Southern soul with a...

Continue Reading